NASDAQ:CYCCP Cyclacel Pharmaceuticals (CYCCP) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free CYCCP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$7.14▼$7.3050-Day Range$5.00▼$6.0352-Week Range$4.25▼$8.07Volume395 shsAverage Volume604 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield8.40%Price TargetN/A Stock AnalysisStock AnalysisCompetitorsDividendHeadlinesSocial MediaStock AnalysisCompetitorsDividendHeadlinesSocial Media Get Cyclacel Pharmaceuticals alerts: Email Address Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCCP)Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.Read More Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… CYCCP Stock News HeadlinesMay 2, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesMay 2, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesMay 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 30, 2024 | msn.com$8 Million Private Placement Announcement Sends Biotech FlyingApril 30, 2024 | investorplace.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesApril 30, 2024 | marketwatch.comCyclacel Pharmaceuticals Withdraws Securities Offering SEC FilingApril 1, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerMay 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 1, 2024 | globenewswire.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerMarch 19, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 13, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditFebruary 20, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceFebruary 20, 2024 | globenewswire.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceJanuary 19, 2024 | msn.comCyclacel Pharmaceuticals files to sell 411K shares of common stockJanuary 9, 2024 | investorplace.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?December 22, 2023 | msn.comCyclacel Pharmaceuticals announces registered direct and private placement offeringDecember 18, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNovember 30, 2023 | finance.yahoo.comCyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNovember 14, 2023 | msn.comCyclacel Pharmaceuticals GAAP EPS of -$0.49 misses by $0.13November 14, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNovember 7, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Release Third Quarter 2023 Financial ResultsAugust 19, 2023 | finance.yahoo.comCYCC Aug 2023 2.500 callAugust 10, 2023 | finance.yahoo.comQ2 2023 Cyclacel Pharmaceuticals Inc Earnings CallSee More Headlines Receive CYCCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CYCCP CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone+1-908-5177330FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Spiro George Rombotis (Age 62)Pres, CEO & Exec. Director Comp: $772.64kMr. Paul McBarron (Age 60)Exec. VP of Fin., CFO, COO, Sec. & Exec. Director Comp: $391.91kDr. Mark H. Kirschbaum M.D. (Age 60)Sr. VP & Chief Medical Officer Comp: $354.73kMs. Gill Christie (Age 64)Director of HR Dr. Robert Westwood Ph.D. (Age 77)Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. Key Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors CYCCP Stock Analysis - Frequently Asked Questions How often does Cyclacel Pharmaceuticals pay dividends? What is the dividend yield for Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals declared a quarterly dividend on Friday, January 12th. Shareholders of record on Monday, January 22nd will be paid a dividend of $0.15 per share on Thursday, February 1st. This represents a $0.60 annualized dividend and a yield of 8.22%. The ex-dividend date of this dividend is Friday, January 19th. Read our dividend analysis for CYCCP. Is Cyclacel Pharmaceuticals a good dividend stock? Cyclacel Pharmaceuticals (NASDAQ:CYCCP) pays an annual dividend of $0.60 per share and currently has a dividend yield of 0.12%. Read our dividend analysis for CYCCP. This page (NASDAQ:CYCCP) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
